MedPage Today - "Avandia's Future Still Bleak?" - Kristina Fiore
An FDA panel recommendation to loosen restrictions on the controversial diabetes drug rosiglitazone (Avandia) isn't likely to affect how -- or whether -- doctors prescribe it, according to experts interviewed by MedPage Today.
"Based on the increasing availability of other anti-diabetic therapy such as the dipeptidyl peptidase 4 (DPP-4) inhibitors and glucagon like peptide-1 (GLP-1) agonists, other options are available to improve glucose control," said Robert Rosenson, MD, of the Icahn School of Medicine at Mount Sinai.
- Dr. Robert Rosenson, Professor, Medicine, Cardiology, Icahn School of Medicine at Mount Sinai